Preliminary data from a Phase 2 clinical trial evaluating NuCana’s (NASDAQ:NCNA) Acelarin (NUC-1031) in heavily pretreated patients with platinum-resistant ovarian cancer showed a treatment effect.
45 patients who received at least three prior
lines of chemo were evaluable for response. There were three responders,
one complete, and 16 with stable cancer implying a disease control rate
(DCR) of 42% (n=19/45). The response rate and DCR improved to 13% and
83%, respectively, in 23 patients who received two or more cycles of
Acelarin.
Consistent with its December 2019 announcement that
it is focusing its resources on Acelarin in biliary tract cancer and
NUC-3373 in colorectal cancer, the company will not proceed with the
second part of the trial.
The company says Acelarin, based on its ProTide
technology, is a “pre-activated” version of gemcitabine, engineered to
outperform the chemo agent by virtue of its ability to overcome cancer
cells’ resistance mechanisms. A Phase 3 study comparing Acelarin to
gemcitabine in pancreatic cancer patients failed, however.
Shares up 4% after hours.
https://seekingalpha.com/news/3550329-nucanas-acelarin-shows-positive-action-in-mid-stage-ovarian-cancer-study
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.